INVA— Innoviva, Inc.

MaterialsPharmaceuticals$1.5B mkt cap

Metric	FY2024	FY2023	FY2022	FY2021
Total revenue	$358.7M+15.5%	$310.5M-6.3%	$331.3M-15.4%	$391.9M
Selling, general and administrative	$115.7M+17.8%	$98.2M+54.6%	$63.5M+292.5%	$16.2M
Research and development	$13.7M-59.7%	$33.9M-18.1%	$41.4M+7093.1%	$576K
Amortization of acquired intangible assets	$25.9M+18.9%	$21.8M+290.3%	$5.6M	$0
Gain on sale of Theravance Respiratory Company, LLC ("TRC")	$0	$0+100.0%	-$266.7M	$0
Loss on extinguishment of debt	$0	$0-100.0%	$20.7M	$0
Changes in fair values of equity method investments, net	$64.3M+183.0%	-$77.4M-147.8%	$161.7M+291.7%	-$84.4M
Changes in fair value of equity and long-term investments, net	$59.2M+631.6%	-$11.1M-31.5%	-$8.5M-27.5%	-$6.6M
Interest and dividend income	-$19.1M-21.0%	-$15.8M-148.4%	-$6.4M-246.3%	-$1.8M
Interest expense	$22.2M+15.9%	$19.2M+21.3%	$15.8M-17.2%	$19.1M
Other expense, net	$3.0M-39.7%	$5.0M+47.3%	$3.4M-7.0%	$3.6M
Total expenses, net	$321.3M+176.1%	$116.4M+162.1%	$44.4M+183.1%	-$53.4M
Income before income taxes	$37.4M-80.7%	$194.1M-32.4%	$286.9M-35.6%	$445.3M
Income tax expense, net	$14.0M-2.6%	$14.4M-78.4%	$66.7M-12.8%	$76.4M
Net income	$23.4M-87.0%	$179.7M-18.4%	$220.3M-40.3%	$368.8M
Net loss attributable to noncontrolling interests	$0	$0-100.0%	$6.3M-93.8%	$103.0M
Net income attributable to Innoviva stockholders	$23.4M-87.0%	$179.7M-16.0%	$213.9M-19.5%	$265.9M
Basic net income per share attributable to Innoviva stockholders	$370.00-86.5%	$2750.00-10.4%	$3070.00-5.2%	$3240.00
Diluted net income per share attributable to Innoviva stockholders	$360.00-83.6%	$2200.00-7.2%	$2370.00-17.4%	$2870.00
Shares used to compute basic net income per share	$62726000.00-4.1%	$65435000.00-6.0%	$69644000.00-15.1%	$82062000.00
Shares used to compute diluted net income per share	$74187000.00-14.6%	$86876000.00-8.8%	$95248000.00+1.0%	$94310000.00
Royalty revenue
Net product sales
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)	$36.6M-10.8%	$41.0M+197.5%	$13.8M	$0
License and other revenue
License
Cost of license revenue	$0-100.0%	$1.6M	$0	$0

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.